To the Editor: Racial/ethnic differences in general health care utilization exist in the United States. 1 Little is known about health care utilization among racial/ethnic groups for skin diseases, including for psoriasis, the most prevalent immune-mediated disease. 2 We aimed to evaluate health care utilization for psoriasis by race/ethnicity using populationbased data derived from the Medical Expenditure Panel Surveys, the most complete source of information on health care utilization, cost, and health insurance coverage in the United States. 3 This study was granted exempt status by the University of Pennsylvania Institutional Review Board.
We conducted a cohort study using Medical Expenditure Panel Survey data pooled from the years 2001 to 2013. The study population was limited to subjects who reported having psoriasis. The primary explanatory variable was race/ethnicity categorized as non-Hispanic white (reference), Hispanic white, and non-Hispanic minority (black, Asian, Native Hawaiian, Pacific Islander, Native American, Alaskan Native, and multiracial); Hispanic nonwhites were excluded because of small numbers. Health care utilization outcomes included the number of ambulatory visits (with any provider), number of prescriptions, and any ambulatory dermatology visit for psoriasis. Additional characteristics of interest included age, sex, the presence of a spouse in the household, census region of residence, highest level of education, health insurance type, household income, medical comorbidity, systemic psoriasis treatment, duration of psoriasis follow-up, and survey year. Multivariable regression was performed to assess the independent association between race/ ethnicity and each health care utilization outcome. All analyses accounted for the complex survey design and population-based weights.
A total of 842 respondents reported having psoriasis, corresponding to more than 1.6 million individuals with self-reported psoriasis in the United States. Baseline characteristics of the study population are summarized in Table I . In adjusted analyses, non-Hispanic racial minorities reported fewer ambulatory visits for psoriasis than non-Hispanic whites (incidence rate ratio 0.54 [95% confidence interval {CI} 0.38-0.77]; Table II ). This relative difference equates to an absolute difference of 1.24 (95% CI 0.62-1.85) fewer visits per person per year and a total of more than 3 million fewer visits per year among non-Hispanic racial minorities versus non-Hispanic whites with psoriasis. Non-Hispanic minorities were also less likely to report having seen a dermatologist for psoriasis than non-Hispanic whites (odds ratio 0.59 [95% CI 0.36-0.95]; Table II ). In contrast, the number of prescriptions obtained for psoriasis was not significantly different among racial/ethnic groups (Table III) . All findings were robust to a sensitivity analysis that excluded individuals with reported oral systemic or biologic use (7.1% of the study population). Study limitations include that we relied on selfreported information, which may be subject to error; our small sample size precluded the analysis of certain minority populations and evaluation of systemic therapies as an outcome; and there was a lack of direct information on psoriasis severity.
Our new identification of disparities in ambulatory health care utilization for psoriasis among nonHispanic minorities is particularly notable in light of previous data suggesting that racial/ethnic minorities have more severe psoriasis 4, 5 and poorer quality of life 5 because of their skin disease compared with whites. Additional studies to understand why differences in health care utilization exist are y Adjusted IRRs and 95% CIs were calculated using negative binomial regression adjusting for age, sex, poverty level, census region, marital status (spouse in household), education level, and health insurance type, accounting for the duration of psoriasis follow-up. z Non-Hispanic minority includes black, Asian/Native Hawaiian/Pacific Islander, American Indian/Alaskan Native, and multiracial.
necessary to achieve equitable care for all patients with psoriasis. To the Editor: Frontal fibrosing alopecia (FFA) is a cicatricial alopecia affecting the frontal and temporal hairlines. 1 The incidence of this condition is increasing, and currently, little is known about the likelihood of stabilization, factors affecting prognosis, and the preferred treatment approach. [2] [3] [4] With institutional review board approval, we reviewed the records of FFA patients with at least 3 months of follow-up and tracked patient progress at each visit by assessing hairline measurements ( from the outer canthi or glabella to frontal hairline) and using trichoscopy (1003 magnification). Disease stabilization was defined as no further hairline recession, eyebrow loss, or evidence of active inflammation (eg, perifollicular erythema, follicular hyperkeratosis). Statistical analyses were conducted using the t test, chi-square test, or Fisher's exact test and log-rank tests.
Our study identified 92 patients (98% of which were women) with FFA; notably, 94.6% of these patients displayed eyebrow involvement (Table I) . Average age of onset for FFA was 55 years, and patients had an average of 21.4 months of follow-up at our clinic (range 3-106 months). Although patients with classic lichen planopilaris typically experience symptoms (including pruritus and pain), 5 only 14.1% of the patients in this study reported symptoms at the initial visit. Approximately 11% of patients had a concomitant autoimmune disease; most commonly hypothyroidism (7.6% of patients). Regarding prognosis, 70.7% (65/92) of patients stabilized with treatment (Table II) after an average of 10.4 (range 1-72) months. Although 27 patients did not stabilize, 10 of them had not yet reached 10 months of follow-up by the time of chart review. We found that a younger age of onset was significantly associated with a less severe disease course ( fewer total centimeters of hairline lost, P ¼ .0012). Family history of hair disorders seemingly did not affect prognosis (P ¼ .4217).
